Heart failure is a clinical syndrome with many possible causes and levels of severity. The 2026 ESC heart-failure guidelines update classification by left-ventricular ejection fraction and introduce a stage-based framework that emphasizes prevention, early recognition and timely intervention. For an international patient, the useful question is therefore not simply which procedure treats heart failure, but what is causing the syndrome, which phenotype and stage are present, whether guideline-directed treatment has been optimized, and whether a structural, rhythm, coronary or advanced-heart-failure intervention is relevant.
Define the cause, phenotype and severity before choosing treatment
A heart-failure diagnosis should trigger an etiologic work-up rather than a generic treatment package. German university centers may review ventricular function, valve disease, coronary disease, rhythm disorders, cardiomyopathy, prior myocarditis, infiltrative disease and major comorbidities before recommending a pathway.
- Recent echocardiography with ejection fraction and valve assessment
- ECG and rhythm-monitor results when relevant
- Cardiac MRI or coronary imaging when already performed
- Laboratory results including kidney function and natriuretic peptides when available
- Current medication with doses and recent changes
- History of hospitalizations, fluid retention and exercise limitation
- Previous cardiac procedures, devices or surgery
Medical treatment is central, not a waiting period before a procedure
Contemporary heart-failure care uses evidence-based medication and management of congestion, blood pressure, kidney disease, diabetes and other comorbidities according to the individual phenotype. The exact regimen and sequence depend on clinical status, kidney function, blood pressure, rhythm and tolerability and require clinician supervision rather than self-directed medication changes.
Coronary, valve and rhythm disease may create connected treatment pathways
Heart failure can result from or be worsened by coronary artery disease, severe valve disease and arrhythmias. When one of these is clinically important, the treatment plan may include revascularization, valve intervention, rhythm treatment or another targeted strategy in addition to heart-failure medication rather than instead of it.
Pacemaker, CRT and ICD decisions depend on the electrical and ventricular profile
Selected patients may be assessed for pacing, cardiac resynchronization therapy or an implantable cardioverter-defibrillator. Device selection depends on rhythm, conduction pattern, ventricular function, symptoms, underlying disease and expected benefit; a device should not be chosen from a brand or package list before electrophysiology and heart-failure review.
Advanced heart failure requires a different level of evaluation
Repeated decompensation, severe functional limitation despite optimized treatment, progressive organ dysfunction or dependence on advanced support can trigger referral to an advanced-heart-failure center. Such centers can assess candidacy for mechanical circulatory support, heart transplantation or other specialized strategies. Referral for evaluation does not mean that a patient will necessarily receive an LVAD or transplant.
Plan continuity of care before travelling
Heart failure usually requires long-term medication titration, laboratory monitoring, volume assessment and follow-up after any intervention. International patients should clarify which parts of treatment can realistically be completed in Germany and which clinician will continue monitoring after return home.
Sources and review
This guide was last source-reviewed on 2026-08-31.